• Bortezomib Successfully Reduces Monoclonal Serum Free Light Chain Levels in a Patient with Recurrent Myeloma and Cast Nephropathy in the Renal Transplant.

Bortezomib Successfully Reduces Monoclonal Serum Free Light Chain Levels in a Patient with Recurrent Myeloma and Cast Nephropathy in the Renal Transplant.

 

Kumar V, Elkins S, Gaston RS, Prendergast MB, Reddy V, Cook WJ, Sanders PW.

Clinical Transplants 2009, Chapter 44


Abstract

Bortezomib can be used to successfully treat acute kidney injury in the renal transplant allograft due to light chain cast nephropathy from recurrent multiple myeloma.     

Bortezomib Successfully Reduces Monoclonal Serum Free Light Chain Levels in a Patient with Recurrent Myeloma and Cast Nephropathy in the Renal Transplant.

  • Product Code: CT09_CH44
  • Availability: In Stock
  • $5.00